By Paul Armentano, NORML Deputy Director
Senate Bill 271 permits physicians to 'recommend' rather than 'prescribe' medical cannabis therapy. The change allows doctors to authorize cannabis without running afoul of federal law, which prohibits the prescription of a schedule I controlled substance.
The measure also expands the pool of conditions eligible for cannabis therapy to include the following: "cancer, positive status for human immunodeficiency virus, acquired immune deficiency syndrome, cachexia or wasting syndrome, seizure disorders, epilepsy, spasticity, Crohn's disease, muscular dystrophy, or multiple sclerosis."
The bill does not amend language in the state's Therapeutic Research Act limiting the preparation of medicinal cannabis products to non-herbal formulations, nor does it address provisions limiting state-licensed cannabis cultivation to a single provider, or the dispensing of cannabis products to no more than ten licensed pharmacies. Those restrictions were put in place by legislation signed into law last year. Separate legislation, SB 180, which explicitly immunizes the program's participants from state criminal prosecution, remains pending in the House and is anticipated to be voted on as early as next week.
Senate Bill 271 does include language requiring the Louisiana State University Agricultural Center and the Southern University Agricultural Center to decide whether or not they wish to seek licensing to grow medical marijuana for the state's program by September 2, 2016.
You can read the enrolled measure here.
Louisiana is set to become the 25th state to permit for the physician-supervised use of medical cannabis and/or cannabis-infused preparations for qualified patients.